Akero Therapeutics, Inc.
$54.65
+0.0000%Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -14.6).
Valuation inputs: P/E -14.6, earnings yield N/A, momentum 0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -33.6%, ROIC -36.3%).
Profitability stack: net margin 0.0%, ROE -33.6%, ROIC -36.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +9.2%, momentum 0.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Akero Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Akero Therapeutics, Inc. Fair Value Envelope
No Revenue Data
AKRO has not reported any revenue values in the available annual periods.
Akero Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
AKRO has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
AKRO has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
AKRO has not reported any net profit margin values in the available annual periods.
Akero Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Akero Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Akero Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that AKRO stock may experience modest gains over the coming 12 months. The consensus 1-year price target stands at 54.67, with estimates ranging from a low of 54.00 to a high of 56.00.
The consensus 1-year price target stands at 54.67, with estimates ranging from a low of 54.00 to a high of 56.00.
Analyst Consensus Analysis
Upside Potential
Fair value territory. Stock trading near consensus target suggests limited near-term catalysts. Focus on fundamental developments.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Efficient pricing: Stock trading at fair value with strong consensus suggests market has priced in expectations. Look for fundamental inflection points or new catalysts to drive meaningful moves.
Akero Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.05M worth of AKRO shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
39.7K
2.06M
-2.1M
-$2.06M
9-12 Months
0
0.00
93.4K
4.99M
-5.0M
-$4.99M
Top Buyers
No buying activity
Top Sellers
Cheng Andrew
Director, Officer: President And Ceo
$3.30M
Rolph Timothy
Officer: Chief Scientific Officer
$2.16M
Young Jonathan
Officer: Chief Operating Officer
$509K
Yale Catriona
Officer: Chief Development Officer
$391K
White William Richard
Officer: Chief Financial Officer
$269K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.05M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
akro Dividend History
Learning Layer
Related Guides
Build conviction on AKRO by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.